Granules India Ltd News Today

Here are some of the stocks that may see significant price movement today.: Hindustan Aeronautics, BEL, Waaree Renewable, etc.

The five-day inspection ran from June 16 to June 20, 2025

The firm’s net debt fell by ₹136 crore to ₹706.1 crore, with a comfortable net debt-to-EBITDA at 0.75x

The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.

Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.

The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.

Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).

The USFDA has also noted a repeat observation from the company's January 2023 inspection.

Glycopyrrolate Oral Solution is an anticholinergic medication used to treat pediatric patients aged 3 to 16 years with neurological conditions that cause drooling.